Market Overview

UPDATE: Stifel Nicolaus Raises PT to $85 on Gilead Sciences on HCV Data

Share:
Related GILD
What Does The Johnson & Johnson/Achillion Deal Mean For HCV Competitors?
5 NASDAQ Healthcare Stocks With The Highest EPS
Seeking Alpha's Biotech Weekly: J&J-Achillion Vs. Gilead, MannKind's Marketing, And More (Seeking Alpha)

Stifel Nicolaus maintained its Buy rating on Gilead Sciences (NASDAQ: GILD) and increased its price target from $80 to $85.

Stifel Nicolaus commented, "Twelve week sofosbuvir plus BMY's NS5a daclatasvir treatment achieved an impressive SVR4 of 98% in treatment naïve genotype 1 patients, and the same combo with ribavirin achieved a 95% SVR4. … On the Abbott investor call held last night, ABT management indicated that they expect data from its six-trial registrational program in 2013 with market launch in 2015."

Gilead Sciences closed at $73.93 on Monday.

Latest Ratings for GILD

DateFirmActionFromTo
Apr 2015OppenheimerAssumesOutperform
Feb 2015Credit SuisseDowngradesOutperformNeutral
Feb 2015CitigroupMaintainsBuy

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (GILD)

Around the Web, We're Loving...

Get Benzinga's Newsletters